$Citius Pharmaceuticals (CTXR.US)$ NEWS Citius Pharmaceutica...
NEWS
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals announced positive topline results from its Phase 3 clinical trial of Mino-Lok, an antibiotic lock solution for catheter-associated infections. The trial achieved its primary endpoint with a statistically significant improvement in time to catheter failure (p=0.0006). Secondary endpoints showed a higher percentage of patients retaining their catheters compared to the control arm (p=0.0025). The study involved 241 patients and demonstrated Mino-Lok's efficacy and safety. The company plans to engage with the FDA for further development.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
748Followers
75Following
4802Visitors
Follow